IMMUNO-ONCOLOGY INSIGHTS

Understanding and overcoming mechanisms of tumor resistance

Guest Editor:
Brent Hanks, Assistant Professor, Medicine, Pharmacology & Cancer Biology at Duke University
Brent Hanks
Assistant Professor, Medicine, Pharmacology & Cancer Biology at Duke University
Brent A. Hanks, M.D., Ph.D. is the William Dalton Family Assistant Professor of Medical Oncology in the Departments of Medicine and Pharmacology and Cancer Biology at Duke University with a dual appointment with the Duke Cancer Institute. Dr. Hanks completed his medical degree along with a Ph.D. in tumor immunology while in the Medical Scientist Training Program at Baylor College of Medicine. Dr. Hanks went on to complete his internal medicine residency training and his hematology and oncology fellowship training at Duke University. He now manages a basic and translational research lab focusing on understanding biochemical mechanisms of tumor-mediated immune evasion and immunotherapy resistance in cancer. More recently, his lab is also exploring the underlying mechanisms associated with immunotherapy-associated toxicities. In addition to his research efforts, he is also a medical oncologist and manages patients with advanced skin cancers including melanoma and Merkel cell carcinoma. Using an array of experimental techniques, his labs' research goals are to develop novel strategies to enhance the efficacy of checkpoint inhibitor and vaccine immunotherapy while also developing predictive biomarkers to better guide the management of cancer patients with immunotherapeutic agents.
January 2021

  • Towards an integrated understanding of immunotherapy resistance

    Towards an integrated understanding of immunotherapy resistance

    11 February 2021
    Foreword
    Brent A Hanks
    Brent A Hanks
    Associate Professor of Medical Oncology in the Department of Medicine and Assistant Professor in the Department of Pharmacology and Cancer Biology, Duke University
    Brent A. Hanks, M.D., Ph.D. is the William Dalton Family Assistant Professor of Medical Oncology in the Departments of Medicine and Pharmacology and Cancer Biology at Duke University with a dual appointment with the Duke Cancer Institute. Dr. Hanks completed his medical degree along with a Ph.D. in tumor immunology while in the Medical Scientist Training Program at Baylor College of Medicine. Dr. Hanks went on to complete his internal medicine residency training and his hematology and oncology fellowship training at Duke University. He now manages a basic and translational research lab focusing on understanding biochemical mechanisms of tumor-mediated immune evasion and immunotherapy resistance in cancer. More recently, his lab is also exploring the underlying mechanisms associated with immunotherapy-associated toxicities. In addition to his research efforts, he is also a medical oncologist and manages patients with advanced skin cancers including melanoma and Merkel cell carcinoma. Using an array of experimental techniques, his labs' research goals are to develop novel strategies to enhance the efficacy of checkpoint inhibitor and vaccine immunotherapy while also developing predictive biomarkers to better guide the management of cancer patients with immunotherapeutic agents.
  • Leveraging the power for genomics for immuno-oncology

    T Golub
    Todd Golub
    Founding Core Member, Chief Scientific Officer, and Director of the Cancer, Program at the Broad, Institute of MIT and Harvard
    4 February 2021
    Interview
  • Towards an integrated understanding of immunotherapy resistance

    B Hanks
    Brent A Hanks
    Associate Professor of Medical Oncology in the Department of Medicine and Assistant Professor in the Department of Pharmacology and Cancer Biology, Duke University
    Brent A. Hanks, M.D., Ph.D. is the William Dalton Family Assistant Professor of Medical Oncology in the Departments of Medicine and Pharmacology and Cancer Biology at Duke University with a dual appointment with the Duke Cancer Institute. Dr. Hanks completed his medical degree along with a Ph.D. in tumor immunology while in the Medical Scientist Training Program at Baylor College of Medicine. Dr. Hanks went on to complete his internal medicine residency training and his hematology and oncology fellowship training at Duke University. He now manages a basic and translational research lab focusing on understanding biochemical mechanisms of tumor-mediated immune evasion and immunotherapy resistance in cancer. More recently, his lab is also exploring the underlying mechanisms associated with immunotherapy-associated toxicities. In addition to his research efforts, he is also a medical oncologist and manages patients with advanced skin cancers including melanoma and Merkel cell carcinoma. Using an array of experimental techniques, his labs' research goals are to develop novel strategies to enhance the efficacy of checkpoint inhibitor and vaccine immunotherapy while also developing predictive biomarkers to better guide the management of cancer patients with immunotherapeutic agents.
    11 February 2021
    Foreword
  • Infiltrating solid tumors with engineered T cells

    A Quintas-Cardama
    Alfonso Quintás-Cardama, MD
    Chief Medical Officer of TCR² Therapeutics
    Alfonso Quintás-Cardama joined TCR² Therapeutics in 2017 as Chief Medical Officer. He brings nearly two decades of experience leading clinical strategy and regulatory filings for multiple oncology therapeutics resulting in market approval. Dr. Quintás-Cardama was the clinical development head of the Cell & Gene Therapies Unit at GlaxoSmithKline where he was responsible for the full clinical development strategy, execution and collaboration with Adaptimmune on affinity enhanced T-cell therapies. Previously, he served as Global Clinical Leader of Novartis’ now approved Kymriah™ (tisagenlecleucel) CTL019 program and was an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center. Dr. Quintás-Cardama earned his MD from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine, Albert Einstein College of Medicine in New York and a Hematology and Oncology fellowship at The University of Texas, MD Anderson Cancer Center.
    4 February 2021
    Interview
  • Progress and challenges for T cell receptor engineered T cells for cancer therapy

    I Stromnes
    Ingunn M Stromnes PhD
    Department of Microbiology and Immunology, Center for Immunology, Center for Genome Engineering and Masonic Cancer Center, University of Minnesota Medical School, Minneapolis, MN 55414, USA
    3 February 2021
    Expert Insight
  • Antigen-presenting dendritic cells as targets for cancer immunotherapy

    D Munn,
    David H. Munn
    Georgia Cancer Center and Department of Pediatrics, Medical College of Georgia, Augusta University, Augusta GA 30912, USA dmunn@augusta.edu
    R Pacholczyk,
    Rafal Pacholczyk
    Georgia Cancer Center and Department of Medicine, Medical College of Georgia, Augusta University, Augusta GA 30912, USA rpacholczyk@augusta.edu
    M Sharma
    Madhav D. Sharma
    Georgia Cancer Center and Department of Pediatrics, Medical College of Georgia, Augusta University, Augusta GA 30912, USA msharma@augusta.edu
    29 January 2021
    Commentary
  • Solving the puzzle of solid tumor resistance to immunotherapy

    P Adusumilli
    Prasad Adusumilli
    Deputy Chief and Attending, Thoracic Surgery; Vice Chair, Dept. of Surgery; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center; Director, Mesothelioma Program, Memorial Sloan-Kettering Cancer Center, NY, USA
    Prasad Adusumilli is a thoracic surgeon with expertise in the management of cancers in the chest including primary (lung cancer, mesothelioma, thymoma, esophageal cancer) and metastatic tumors. His laboratory research, supported by NIH RO1 and DoD awards, focuses on tumor immunology, and chimeric antigen receptor (CAR) T-cell-mediated immunotherapy for cancers. Over the years, he has developed clinically-relevant solid tumor mouse models and modeled regional delivery of novel biological therapies including oncolytic viruses and immune cells in these models. This research has yielded mechanistic data that has been translated and is now in clinical trials for patients with lung cancer, mesothelioma, and breast cancer. His ongoing research focuses on combination immunotherapy to reactivate both CAR T-cell and endogenous immunity by use of cell-intrinsic and extrinsic checkpoint blockade strategies; combination of CAR T cells with antiPD1 agent is now in Phase 2 clinical trial. As Head of solid tumor cell therapy in the Cellular Therapeutics Center at the Memorial Sloan Kettering (MSK) Cancer Center, he conducts and coordinates cell therapy clinical trials for solid tumor patients.
    21 January 2021
    Interview